Advertisement

Folia Microbiologica

, Volume 63, Issue 4, pp 517–523 | Cite as

First report of Candida bracarensis in Mexico: hydrolytic enzymes and antifungal susceptibility pattern

  • Rogelio de J. Treviño-Rangel
  • José F. Espinosa-Pérez
  • Hiram Villanueva-Lozano
  • Alexandra M. Montoya
  • Angel Andrade
  • Alexandro Bonifaz
  • Gloria M. GonzálezEmail author
Short Communication

Abstract

Candida bracarensis is an emerging cryptic species within the Candida glabrata clade. To date, little is known about its epidemiology, virulence, and antifungal susceptibility. This study documents the occurrence of C. bracarensis for the first time in Mexico and focuses on its in vitro production of hydrolytic enzymes, as well as antifungal susceptibility to echinocandins. This strain was isolated from a vaginal swab of a female with vulvovaginal candidosis; exhibited a very strong activity of aspartyl proteinase, phospholipase, and hemolysin; and was susceptible to caspofungin, anidulafungin, and micafungin (MIC = 0.031 μg/mL). Data obtained could contribute to the knowledge of the epidemiology and virulence attributes of this yeast as a fungal opportunistic human pathogen.

Notes

Acknowledgments

We are grateful to Sergio Lozano-Rodríguez, M.D., for his review of the manuscript prior to submission.

Funding

This work was supported by internal resources of the Department of Microbiology, School of Medicine, UANL.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126CrossRefPubMedGoogle Scholar
  2. Alcoba-Flórez J, Méndez-Alvarez S, Cano J, Guarro J, Pérez-Roth E, del Pilar Arévalo M (2005) Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 43:4107–4111.  https://doi.org/10.1128/JCM.43.8.4107-4111.2005 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Al-Rawahi GN, Roscoe DL (2013) Ten-year review of candidemia in a Canadian tertiary care centre: predominance of non-albicans Candida species. Can J Infect Dis Med Microbiol 24:e65–e68PubMedPubMedCentralCrossRefGoogle Scholar
  4. Angoulvant A, Guitard J, Hennequin C (2016) Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance. FEMS Yeast Res 16:fov114.  https://doi.org/10.1093/femsyr/fov114 PubMedCrossRefGoogle Scholar
  5. Bishop JA, Chase N, Magill SS, Kurtzman CP, Fiandaca MJ, Merz WG (2008) Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: susceptibility data and documentation of presumed infection. J Clin Microbiol 46:443–446.  https://doi.org/10.1128/JCM.01986-07 CrossRefPubMedGoogle Scholar
  6. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F (2014) Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 20:1149–1155.  https://doi.org/10.3201/eid2007.140087 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD (2017) In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. J Antimicrob Chemother 72:1355–1358.  https://doi.org/10.1093/jac/dkx008 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM (2008) Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 46:933–938.  https://doi.org/10.1128/JCM.02116-07 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Chakrabarti A, Nayak N, Talwar P (1991) In vitro proteinase production by Candida species. Mycopathologia 114:163–168CrossRefPubMedGoogle Scholar
  10. Chang CC, Slavin MA, Chen SC (2017) New developments and directions in the clinical application of the echinocandins. Arch Toxicol 91:1613–1621.  https://doi.org/10.1007/s00204-016-1916-3 CrossRefPubMedGoogle Scholar
  11. Chapeland-Leclerc F, Hennequin C, Papon N, Noël T, Girard A, Socié G, Ribaud P, Lacroix C (2010) Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54:1360–1362.  https://doi.org/10.1128/AAC.01138-09 CrossRefPubMedGoogle Scholar
  12. Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11–41.  https://doi.org/10.2165/11585270-000000000-00000 CrossRefPubMedGoogle Scholar
  13. Chowdhary A, Randhawa HS, Khan ZU, Ahmad S, Juneja S, Sharma B, Roy P, Sundar G, Joseph L (2010) First isolations in India of Candida nivariensis, a globally emerging opportunistic pathogen. Med Mycol 48:416–420.  https://doi.org/10.1080/13693780903114231 CrossRefPubMedGoogle Scholar
  14. Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd edn. CLSI, Wayne, PAGoogle Scholar
  15. Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, Nouér SA, Nucci M (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489–1498.  https://doi.org/10.1007/s00134-014-3400-y CrossRefPubMedPubMedCentralGoogle Scholar
  16. Correia A, Sampaio P, James S, Pais C (2006) Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol 56:313–317.  https://doi.org/10.1099/ijs.0.64076-0 CrossRefPubMedGoogle Scholar
  17. Cuenca-Estrella M, Gomez-Lopez A, Isla G, Rodriguez D, Almirante B, Pahissa A, Rodriguez-Tudela JL (2011) Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia. Med Mycol 49:525–529.  https://doi.org/10.3109/13693786.2010.546373 PubMedCrossRefGoogle Scholar
  18. Figueiredo-Carvalho MH et al (2016) First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes. Mem Inst Oswaldo Cruz 111:51–58.  https://doi.org/10.1590/0074-02760150376 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Fujita S, Senda Y, Okusi T, Ota Y, Takada H, Yamada K, Kawano M (2007) Catheter-related fungemia due to fluconazole-resistant Candida nivariensis. J Clin Microbiol 45:3459–3461.  https://doi.org/10.1128/JCM.00727-07 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Garcia-Effron G, Park S, Perlin DS (2009) Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53:112–122.  https://doi.org/10.1128/AAC.01162-08 CrossRefPubMedGoogle Scholar
  21. Ghannoum MA (2000) Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 13:122–143 table of contentsCrossRefPubMedPubMedCentralGoogle Scholar
  22. Gil-Alonso S, Jauregizar N, Cantón E, Eraso E, Quindós G (2015) In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies. Antimicrob Agents Chemother 59:3615–3618.  https://doi.org/10.1128/AAC.04474-14 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Girão E, Levin AS, Basso M, Gobara S, Gomes LB, Medeiros EA, Costa SF (2008) Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in intensive care units at a Brazilian University hospital. Med Mycol 46:581–588.  https://doi.org/10.1080/13693780802004996 CrossRefPubMedGoogle Scholar
  24. Green MR, Sambrook J (2012) Isolation of high-molecular-weight DNA using organic solvents. In: Green MR (ed) Molecular cloning: a laboratory manual, 4th edn. CSH Press, New YorkGoogle Scholar
  25. Hou X, Xiao M, SCA C, Wang H, Yu SY, Fan X, Kong F, Xu YC (2017) Identification and antifungal susceptibility profiles of Candida nivariensis and Candida bracarensis in a multi-center Chinese collection of yeasts. Front Microbiol 8:5.  https://doi.org/10.3389/fmicb.2017.00005 PubMedPubMedCentralCrossRefGoogle Scholar
  26. Hurley R, De Louvois J (1979) Candida vaginitis. Postgrad Med J 55:645–647CrossRefPubMedPubMedCentralGoogle Scholar
  27. Koga-Ito CY, Lyon JP, Vidotto V, de Resende MA (2006) Virulence factors and antifungal susceptibility of Candida albicans isolates from oral candidosis patients and control individuals. Mycopathologia 161:219–223.  https://doi.org/10.1007/s11046-005-0001-x CrossRefPubMedGoogle Scholar
  28. Kumar CP, Menon T, Sundararajan T, Nalini S, Thirunarayan MA, Rajasekaran S, Venkatadesikalu M (2006) Esterase activity of Candida species isolated from immunocompromised hosts. Rev Iberoam Micol 23:101–103CrossRefPubMedGoogle Scholar
  29. Li J, Shan Y, Fan S, Liu X (2014) Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis. Mycopathologia 178:279–283.  https://doi.org/10.1007/s11046-014-9800-2 CrossRefPubMedGoogle Scholar
  30. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, Diekema DJ (2009) Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 47:1216–1217.  https://doi.org/10.1128/JCM.02315-08 CrossRefPubMedPubMedCentralGoogle Scholar
  31. López-Soria LM et al (2013) First case report of catheter-related fungemia by Candida nivariensis in the Iberian Peninsula. Rev Iberoam Micol 30:69–71.  https://doi.org/10.1016/j.riam.2012.09.001 CrossRefPubMedGoogle Scholar
  32. Luo G, Samaranayake LP, Yau JY (2001) Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 39:2971–2974.  https://doi.org/10.1128/JCM.39.8.2971-2974.2001 CrossRefPubMedPubMedCentralGoogle Scholar
  33. Marriott DJ et al (2009) Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 13:R115.  https://doi.org/10.1186/cc7964 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Morales-López SE et al (2016) Candida glabrata species complex prevalence and antifungal susceptibility testing in a culture collection: first description of Candida nivariensis in Argentina. Mycopathologia 181:871–878.  https://doi.org/10.1007/s11046-016-0052-1 CrossRefPubMedGoogle Scholar
  35. Morales-López S, Dudiuk C, Vivot W, Szusz W, Córdoba SB, Garcia-Effron G (2017) Phenotypic and molecular evaluation of echinocandin susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis strains isolated during 30 years in Argentina. Antimicrob Agents Chemother 61:e00170–e00117.  https://doi.org/10.1128/AAC.00170-17 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Moreira A, Silva S, Botelho C, Sampaio P, Pais C, Henriques M (2015) Candida bracarensis: evaluation of virulence factors and its tolerance to amphotericin B and fluconazole. Mycopathologia 180:305–315.  https://doi.org/10.1007/s11046-015-9925-y CrossRefPubMedGoogle Scholar
  37. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–50.  https://doi.org/10.1093/cid/civ933 CrossRefPubMedGoogle Scholar
  38. Pfaller MA, Diekema DJ (2012) Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50:2846–2856.  https://doi.org/10.1128/JCM.00937-12 CrossRefPubMedPubMedCentralGoogle Scholar
  39. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2008) In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156.  https://doi.org/10.1128/JCM.01901-07 CrossRefPubMedGoogle Scholar
  40. Price MF, Wilkinson ID, Gentry LO (1982) Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 20:7–14CrossRefPubMedGoogle Scholar
  41. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43:2155–2162.  https://doi.org/10.1128/JCM.43.5.2155-2162.2005 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, Chen W, Consortium FB, List FBCA, Bolchacova E, Voigt K, Crous PW, Miller AN, Wingfield MJ, Aime MC, An KD, Bai FY, Barreto RW, Begerow D, Bergeron MJ, Blackwell M, Boekhout T, Bogale M, Boonyuen N, Burgaz AR, Buyck B, Cai L, Cai Q, Cardinali G, Chaverri P, Coppins BJ, Crespo A, Cubas P, Cummings C, Damm U, de Beer ZW, de Hoog GS, del-Prado R, Dentinger B, Dieguez-Uribeondo J, Divakar PK, Douglas B, Duenas M, Duong TA, Eberhardt U, Edwards JE, Elshahed MS, Fliegerova K, Furtado M, Garcia MA, Ge ZW, Griffith GW, Griffiths K, Groenewald JZ, Groenewald M, Grube M, Gryzenhout M, Guo LD, Hagen F, Hambleton S, Hamelin RC, Hansen K, Harrold P, Heller G, Herrera C, Hirayama K, Hirooka Y, Ho HM, Hoffmann K, Hofstetter V, Hognabba F, Hollingsworth PM, Hong SB, Hosaka K, Houbraken J, Hughes K, Huhtinen S, Hyde KD, James T, Johnson EM, Johnson JE, Johnston PR, EBG J, Kelly LJ, Kirk PM, Knapp DG, Koljalg U, Kovacs GM, Kurtzman CP, Landvik S, Leavitt SD, Liggenstoffer AS, Liimatainen K, Lombard L, Luangsa-ard JJ, Lumbsch HT, Maganti H, SSN M, Martin MP, May TW, AR MT, Methven AS, Meyer W, Moncalvo JM, Mongkolsamrit S, Nagy LG, Nilsson RH, Niskanen T, Nyilasi I, Okada G, Okane I, Olariaga I, Otte J, Papp T, Park D, Petkovits T, Pino-Bodas R, Quaedvlieg W, Raja HA, Redecker D, Rintoul TL, Ruibal C, Sarmiento-Ramirez JM, Schmitt I, Schussler A, Shearer C, Sotome K, FOP S, Stenroos S, Stielow B, Stockinger H, Suetrong S, Suh SO, Sung GH, Suzuki M, Tanaka K, Tedersoo L, Telleria MT, Tretter E, Untereiner WA, Urbina H, Vagvolgyi C, Vialle A, Vu TD, Walther G, Wang QM, Wang Y, Weir BS, Weiss M, White MM, Xu J, Yahr R, Yang ZL, Yurkov A, Zamora JC, Zhang N, Zhuang WY, Schindel D (2012) Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. Proc Natl Acad Sci U S A 109:6241–6246.  https://doi.org/10.1073/pnas.1117018109 CrossRefPubMedPubMedCentralGoogle Scholar
  43. Sharma C, Wankhede S, Muralidhar S, Prakash A, Singh PK, Kathuria S, Kumar DA, Khan N, Randhawa HS, Meis JF, Chowdhary A (2013) Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India. Diagn Microbiol Infect Dis 76:46–50.  https://doi.org/10.1016/j.diagmicrobio.2013.02.023 CrossRefPubMedGoogle Scholar
  44. Slifkin M (2000) Tween 80 opacity test responses of various Candida species. J Clin Microbiol 38:4626–4628PubMedPubMedCentralGoogle Scholar
  45. Sobel JD (2007) Vulvovaginal candidosis. Lancet 369:1961–1971.  https://doi.org/10.1016/S0140-6736(07)60917-9 CrossRefPubMedGoogle Scholar
  46. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30:2725–2729.  https://doi.org/10.1093/molbev/mst197 CrossRefPubMedPubMedCentralGoogle Scholar
  47. Tay ST, Lotfalikhani A, Sabet NS, Ponnampalavanar S, Sulaiman S, Na SL, Ng KP (2014) Occurrence and characterization of Candida nivariensis from a culture collection of Candida glabrata clinical isolates in Malaysia. Mycopathologia 178:307–314.  https://doi.org/10.1007/s11046-014-9778-9 CrossRefPubMedGoogle Scholar
  48. Treviño-Rangel Rde J, González JG, González GM (2013) Aspartyl proteinase, phospholipase, esterase and hemolysin activities of clinical isolates of the Candida parapsilosis species complex. Med Mycol 51:331–335.  https://doi.org/10.3109/13693786.2012.712724 CrossRefGoogle Scholar
  49. Treviño-Rangel RJ, Bodden-Mendoza BA, Montoya AM, Villanueva-Lozano H, Elizondo-Zertuche M, Robledo-Leal E, González GM (2017) Phenotypical characterization and molecular identification of clinical isolates of Candida tropicalis. Rev Iberoam Micol 35:17–21.  https://doi.org/10.1016/j.riam.2017.05.002 CrossRefPubMedGoogle Scholar
  50. Wahyuningsih R, SahBandar IN, Theelen B, Hagen F, Poot G, Meis JF, Rozalyani A, Sjam R, Widodo D, Djauzi S, Boekhout T (2008) Candida nivariensis isolated from an Indonesian human immunodeficiency virus-infected patient suffering from oropharyngeal candidiasis. J Clin Microbiol 46:388–391.  https://doi.org/10.1128/JCM.01660-07 CrossRefPubMedGoogle Scholar
  51. Warren TA, McTaggart L, Richardson SE, Zhang SX (2010) Candida bracarensis bloodstream infection in an immunocompromised patient. J Clin Microbiol 48:4677–4679.  https://doi.org/10.1128/JCM.01447-10 CrossRefPubMedPubMedCentralGoogle Scholar
  52. White TJ, Bruns T, Lee S, Taylor J (1990) Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA GD, Sninsky JJ, White TJ (ed) PCR protocols: a guide to methods and applications. Academic Press, San Diego, pp 315–322Google Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i. 2018

Authors and Affiliations

  • Rogelio de J. Treviño-Rangel
    • 1
  • José F. Espinosa-Pérez
    • 1
  • Hiram Villanueva-Lozano
    • 1
  • Alexandra M. Montoya
    • 1
  • Angel Andrade
    • 1
  • Alexandro Bonifaz
    • 2
  • Gloria M. González
    • 1
    Email author
  1. 1.Department of Microbiology, School of MedicineUniversidad Autónoma de Nuevo LeónMonterreyMexico
  2. 2.Dermatology Service and Mycology DepartmentHospital General de México “Dr. Eduardo Liceaga”Mexico CityMexico

Personalised recommendations